Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Complication Clear all
Terminated No phase listed Observational

A Biomarker Screening Protocol for Participants With Solid Tumors

NCT05891197
View directory record Official record
Conditions
Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer
Interventions
Not listed
Lead sponsor
Lyell Immunopharma, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Rocky Mount, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Jul 22, 2026, 9:03 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

NCT04579380
View directory record Official record
Conditions
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
Interventions
tucatinib, trastuzumab, fulvestrant
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
75
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jul 22, 2026, 9:03 AM EDT
Recruiting Phase 2 Interventional

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

NCT06953089
View directory record Official record
Conditions
Solid Tumors
Interventions
DB-1311/BNT324, BNT327, DB-1305/BNT325
Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
15
States / cities
Los Angeles, California • Wheat Ridge, Colorado • Florida City, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 9:03 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037

NCT00884520
View directory record Official record
Conditions
Lung Cancer, Squamous Cell Carcinoma, Head and Neck Cancer, Hepatic Carcinoma, Renal Cell Carcinoma
Interventions
[F-18] VM4-037
Drug
Lead sponsor
Siemens Molecular Imaging
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2010 · Synced Jul 22, 2026, 9:03 AM EDT
Recruiting Phase 1 Interventional

A Study of NX-1607 in Adults With Advanced Malignancies

NCT05107674
View directory record Official record
Conditions
Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
Interventions
NX-1607, Paclitaxel
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jul 22, 2026, 9:03 AM EDT
Recruiting Phase 2 Interventional

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

NCT03175224
View directory record Official record
Conditions
Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Interventions
APL-101 Oral Capsules
Drug
Lead sponsor
Apollomics Inc.
Industry
Eligibility
18 Years and older
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Jul 22, 2026, 9:03 AM EDT
Completed Phase 1 Interventional

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

NCT02071862
View directory record Official record
Conditions
Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Mesothelioma, Fumarate Hydratase (FH)-Deficient Tumors, Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST), Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors, Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations, Tumors Harboring Amplifications in the cMyc Gene
Interventions
CB-839, Pac-CB, CBE, CB-Erl, CBD, CB-Cabo
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
San Francisco, California • Stanford, California • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Jul 22, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

Improving Communication About Serious Illness

NCT01933789
View directory record Official record
Conditions
Critical Illness, Chronic Disease, Terminal Care, Palliative Care, Communication, Advance Care Planning, Neoplasm Metastasis, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive, Heart Failure, End Stage Liver Disease, Kidney Failure, Chronic
Interventions
Communication Feedback Form for Patients with Serious Illness
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
817 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Renton, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Jul 22, 2026, 9:03 AM EDT
Recruiting No phase listed Observational

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

NCT05974150
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer, Acute Myelogenous Leukemia
Interventions
Web based survey
Other
Lead sponsor
Carevive Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
New Haven, Connecticut • Evanston, Illinois • Chapel Hill, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 22, 2026, 9:03 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia

NCT07312227
View directory record Official record
Conditions
Hypertensive Disorder of Pregnancy, Pulmonary Arterial Hypertension, Intrauterine Growth Restriction
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 22, 2026, 9:03 AM EDT
Terminated Phase 2 Interventional Results available

Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer

NCT03050060
View directory record Official record
Conditions
Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Atezolizumab, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Nelfinavir Mesylate, Nivolumab, Pembrolizumab
Drug · Radiation · Other + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Jul 22, 2026, 9:03 AM EDT
Completed Phase 1 Interventional

Safety Study of MGA271 in Refractory Cancer

NCT01391143
View directory record Official record
Conditions
Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Head and Neck Cancer, Bladder Cancer, Non-small Cell Lung Cancer
Interventions
MGA271
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
12
States / cities
Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Jul 22, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

18F-FSPG PET/CT for Cancer Patients on Therapy

NCT02599194
View directory record Official record
Conditions
B-Cell Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Renal Cell Cancer, Progesterone Receptor Negative, Stage III Mesothelioma, Stage III Renal Cell Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Mesothelioma, Stage IV Non-Small Cell Lung Cancer, Stage IV Renal Cell Cancer, Triple-Negative Breast Carcinoma
Interventions
18F-FSPG, 18F-FDG
Drug
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Jul 22, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

Assessing Ventilator Safety in Patients on Pressure-Support Ventilation

NCT05125952
View directory record Official record
Conditions
Acute Respiratory Failure, Mechanical Ventilation Complication, Ventilator-Induced Lung Injury
Interventions
Viasys Avea Ventilator, Philips Respironics NM3 device, Servo U ventilator, Vyaire SmartCath adult nasogastric tube with Esophageal balloon
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 22, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Trial II of Lung Protection With Azithromycin in the Preterm Infant

NCT00319956
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
Hubert Ballard
Other
Eligibility
Up to 72 Hours
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Jul 22, 2026, 9:03 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer

NCT01259284
View directory record Official record
Conditions
Advanced Cancers
Interventions
Atorvastatin, Fish Oil Supplement, Placebo
Drug · Dietary Supplement · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Jul 22, 2026, 9:03 AM EDT
Completed No phase listed Observational

Pleural Catheters Versus Thoracoscopic Pleurodesis

NCT01117740
View directory record Official record
Conditions
Lung Cancer
Interventions
MDASI Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2016 · Synced Jul 22, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

Measuring and Improving the Safety of Test Result Follow-Up

NCT04166240
View directory record Official record
Conditions
Lung Cancer, Breast Cancer, Colon Cancer, Bladder Cancer, Hepatocellular Cancer
Interventions
SAFER TRACKS Intervention
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Houston, Texas • White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jul 22, 2026, 9:03 AM EDT
Terminated Phase 1 Interventional

One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy

NCT00358397
View directory record Official record
Conditions
Tumors
Interventions
Clostridium novyi-NT spores
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Jul 22, 2026, 9:03 AM EDT
Recruiting Phase 1 Interventional

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

NCT06805825
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma, Neuroendocrine Tumors, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Interventions
NN3201
Drug
Lead sponsor
Novelty Nobility, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Jul 22, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

NCT03526250
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
Interventions
Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
115
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jul 22, 2026, 9:03 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Maternal Hyperoxygenation for Intrapartum Fetal Heart Rate Tracing Abnormalities

NCT03996317
View directory record Official record
Conditions
Perinatal Death, Respiratory Distress Syndrome, Newborn, Hypoxic-Ischemic Encephalopathy, Neonatal Seizure, Meconium Aspiration Syndrome, Intracranial Hemorrhages, Neonatal Hypotension
Interventions
Room air
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Jul 22, 2026, 9:03 AM EDT
Completed Not applicable Interventional

The Use of Heliox Via Nasal CPAP to Prevent Early CPAP Failure in Premature Infants: A Feasibility Study

NCT00739115
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Heliox gas
Other
Lead sponsor
Hawaii Pacific Health
Other
Eligibility
1 Minute to 12 Hours
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Jul 22, 2026, 9:03 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

NCT04074967
View directory record Official record
Conditions
Renal Cell Carcinoma, Melanoma, Solid Tumor, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab, Phase II ARRY-614 + nivolumab+ipilimumab (melanoma), Phase II ARRY-614 + nivolumab+ipilimumab (RCC)
Drug
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jul 22, 2026, 9:03 AM EDT